PTAB to Review Moderna’s COVID-19 Vaccine Patents Challenged by Pfizer, BioNTech

In a recent development, the Patent Trial and Appeal Board has decided to evaluate two COVID-19 vaccine patents held by Moderna. These patents have been challenged by Pfizer and BioNTech who allege that they exhibit “unimaginably broad claims directed to a basic idea that was known long before.”

This move represents a significant event as it suggests a potential shift or reassessment in the protection of intellectual property regarding COVD-19 vaccines. This legal challenge could have implications not only for Moderna but also Pfizer and BioNTech who are renowned competitors in the field of vaccine production.

The details of the two disputed patents have not been publicly revealed, which amplifies the interest in this case, as lawyers and legal professionals anticipate the arguments and evidence that will be presented.

For those seeking more detailed information, the original Law360 article discussing the review of Moderna’s COVID-19 vaccine patents by the Patent Trial and Appeal Board, provides comprehensive coverage of this development.